• 1
    Pollack A, Zagars GK, Starkschall G et al. Prostate cancer radiation dose–response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097105
  • 2
    Peeters ST, Heemsbergen WD, Koper PC et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24: 19906
  • 3
    Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294: 12339
  • 4
    Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007; 68: 6829
  • 5
    Cheung MR, Tucker SL, Dong L et al. Investigation of bladder dose and Volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007; 67: 105965
  • 6
    Litwin MS, Fitzpatrick JM, Fossa SD, Newling DW. Defining an international research agenda for quality of life in men with prostate cancer. Prostate 1999; 41: 5867
  • 7
    Van Vulpen M, Van Der Heide UA, Van Moorselaar JR. How quality influences the clinical outcome of external beam radiotherapy for localized prostate cancer. BJU Int 2008; 101: 9447
  • 8
    Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008; 9: 36775
  • 9
    Lips I, Dehnad H, Kruger AB et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 2007; 69: 65661
  • 10
    Yoshimura K, Kamoto T, Nakamura E et al. Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: intensity-modulated radiation therapy versus conformal radiation therapy. Prostate Cancer Prostatic Dis 2007; 10: 28892
  • 11
    Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 2002; 167: 1236
  • 12
    Junius S, Haustermans K, Bussels B et al. Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. Radiat Oncol 2007; 2: 29
  • 13
    Namiki S, Ishidoya S, Tochigi T et al. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy. Jpn J Clin Oncol 2006; 36: 22430
  • 14
    Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001; 51: 98893
  • 15
    Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 125061
  • 16
    Lilleby W, Fossa SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 73543
  • 17
    Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005; 41: 2807
  • 18
    Nederveen AJ, Van Der Heide UA, Hofman P, Welleweerd H, Lagendijk JJ. Partial boosting of prostate tumours. Radiother Oncol 2001; 61: 11726
  • 19
    Van Der Heide UA, Kotte AN, Dehnad H, Hofman P, Lagenijk JJ, Van Vulpen M. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother Oncol 2007; 82: 3845
  • 20
    Hornbrook MC, Goodman MJ. Assessing relative health plan risk with the RAND-36 health survey. Inquiry 1995; 32: 5674
  • 21
    Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 36576
  • 22
    Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res 1996; 5: 21222
  • 23
    Henderson A, Laing RW, Langley SE. Quality of life following treatment for early prostate cancer: does low dose rate (LDR) brachytherapy offer a better outcome? A review. Eur Urol 2004; 45: 13441
  • 24
    Lips IM, Dehnad H, Van Gils CH, Boeken Kruger AE, Van Der Heide UA, Van Vulpen M. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol 2008; 3: 15
  • 25
    Breetvelt IS, Van Dam FS. Underreporting by cancer patients: the case of response-shift. Soc Sci Med 1991; 32: 9817
  • 26
    Aaronson NK, Muller M, Cohen PD et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998; 51: 105568
  • 27
    Pinkawa M, Gagel B, Piroth MD et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 2008; Epub ahead of print
  • 28
    Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology 2003; 62: 70713
  • 29
    Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 180213
  • 30
    Incrocci L, Slob AK, Levendag PC. Sexual (dys) function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys 2002; 52: 68193
  • 31
    Staff I, Salner A, Bohannon R, Panatieri P, Maljanian R. Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy. Cancer 2003; 98: 233543